Compare $MLYS vs $PVLA | Chartloom

Compare

$MLYS vs $PVLA

Mineralys Therapeutics Inc · Palvella Therapeutics Inc

MLYS

Mineralys Therapeutics Inc

PVLA

Palvella Therapeutics Inc

Compare $MLYS vs $PVLA

Comparing Mineralys Therapeutics Inc and Palvella Therapeutics Inc

MLYSMineralys Therapeutics Inc

PVLAPalvella Therapeutics Inc

MLYSMineralys Therapeutics Inc

Market cap

$2.06B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

30.20x

Rev growth (TTM)

—

YTD performance

-34.6%

52W performance

-37.7%

FCF yield

-16.5%

PVLAPalvella Therapeutics Inc

Market cap

$1.99B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-97.2%

YTD performance

38.4%

52W performance

85.4%

FCF yield

-1.8%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

MLYS

PVLA

Detailed metrics comparison

MLYS

Mineralys Therapeutics Inc

PVLA

Palvella Therapeutics Inc

Market Cap

MLYS$2.06B

PVLA$1.99B

Enterprise Value

MLYS$2.02B

PVLA$1.82B

Price

MLYS$23.37

PVLA$138.77

P/E Ratio

MLYSN/A

PVLAN/A

P/S Ratio

MLYS0.00x

PVLA46.64x

EV/Sales

MLYS0.00x

PVLA0.00x

EV/EBITDA

MLYS0.00x

PVLA0.00x

P/B Ratio

MLYS3.79x

PVLA8.80x

P/FCF Ratio

MLYSN/A

PVLAN/A

EV/FCF

MLYS-5.96x

PVLA-49.96x

PEG Ratio

MLYSN/A

PVLAN/A

Forward P/E (NTM)

MLYSN/A

PVLAN/A

Forward P/S (NTM)

MLYS30.20x

PVLAN/A

Revenue (TTM)

MLYS$0

PVLA$0

Revenue Growth (YoY)

MLYSN/A

PVLA-97.2%

Forward Rev Growth

MLYS106.7%

PVLA287.4%

Gross Margin (TTM)

MLYS0.0%

PVLA0.0%

Operating Margin (TTM)

MLYS0.0%

PVLA0.0%

EBITDA Margin (TTM)

MLYS0.0%

PVLA0.0%

Net Margin (TTM)

MLYS0.0%

PVLA0.0%

FCF Margin (TTM)

MLYSN/A

PVLAN/A

Net Income (TTM)

MLYS$-350M

PVLA$-62M

FCF (TTM)

MLYS$-339M

PVLA$-37M

EPS (TTM)

MLYS-$4.13

PVLA-$4.30

ROE (TTM)

MLYS-5797.0%

PVLA-4784.0%

ROA (TTM)

MLYS-5415.0%

PVLA-3833.0%

ROIC (TTM)

MLYS-5571.0%

PVLA-4172.0%

Cash

MLYS$138M

PVLA$188M

Debt

MLYS$98M

PVLA$22M

Net Cash/Debt

MLYS$41M

PVLA$166M

Current Ratio (TTM)

MLYS34.46x

PVLA21.18x

Quick Ratio (TTM)

MLYS34.24x

PVLA21.01x

Debt/Equity (TTM)

MLYS0.18x

PVLA0.10x

Debt/Assets (TTM)

MLYS0.0%

PVLA0.0%

Interest Coverage (TTM)

MLYSN/A

PVLAN/A

Net Debt/EBITDA (TTM)

MLYS0.00x

PVLA0.00x

Beta

MLYS0.64

PVLA-0.19

52W Performance

MLYS-37.7%

PVLA85.4%

YTD Performance

MLYS-34.6%

PVLA38.4%

% from 52W High

MLYS-51.0%

PVLA-14.0%

% from 52W Low

MLYS8.9%

PVLA110.5%

Asset Turnover (TTM)

MLYS0.00x

PVLA0.76x

FCF Yield (TTM)

MLYS-16.5%

PVLA-1.8%

Earnings Yield (TTM)

MLYS-17.0%

PVLA-3.1%

Dividend Yield (TTM)

MLYSN/A

PVLAN/A

Rule of 40

MLYS0.0

PVLA-97.2

EV/GP/RG

MLYSN/A

PVLAN/A

Ticker research

View MLYS research View PVLA research

Metric	MLYS Mineralys Therapeutics Inc	PVLA Palvella Therapeutics Inc
Market & Valuation
Market Cap	$2.06B	$1.99B
Enterprise Value	$2.02B	$1.82B
Price	$23.37	$138.77
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	46.64x
EV/Sales	0.00x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.79x	8.80x
P/FCF Ratio	N/A	N/A
EV/FCF	-5.96x	-49.96x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	30.20x	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	-97.2%
Forward Rev Growth	106.7%	287.4%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-350M	$-62M
FCF (TTM)	$-339M	$-37M
EPS (TTM)	-$4.13	-$4.30
ROE (TTM)	-5797.0%	-4784.0%
ROA (TTM)	-5415.0%	-3833.0%
ROIC (TTM)	-5571.0%	-4172.0%
Financial Health
Cash	$138M	$188M
Debt	$98M	$22M
Net Cash/Debt	$41M	$166M
Current Ratio (TTM)	34.46x	21.18x
Quick Ratio (TTM)	34.24x	21.01x
Debt/Equity (TTM)	0.18x	0.10x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.64	-0.19
52W Performance	-37.7%	85.4%
YTD Performance	-34.6%	38.4%
% from 52W High	-51.0%	-14.0%
% from 52W Low	8.9%	110.5%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.76x
FCF Yield (TTM)	-16.5%	-1.8%
Earnings Yield (TTM)	-17.0%	-3.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-97.2
EV/GP/RG	N/A	N/A
Ticker research	View MLYS research	View PVLA research

Valuation

P/S Ratio

MLYS

0.00x

PVLA

46.64x

EV/FCF

PVLA

-49.96x

MLYS

-5.96x

Growth & revenue

Revenue Growth TTM

PVLA

-97.2%

Forward Revenue Growth

PVLA

287.4%

MLYS

106.7%

Profitability & performance

Gross Margin

MLYS

0.0%

PVLA

0.0%

ROE

PVLA

-4784.0%

MLYS

-5797.0%

FCF Yield %

PVLA

-1.8%

MLYS

-16.5%

52-Week Performance

PVLA

85.4%

MLYS

-37.7%

Detailed metrics comparison

MLYS

Mineralys Therapeutics Inc

PVLA

Palvella Therapeutics Inc

Market Cap

MLYS$2.06B

PVLA$1.99B

Enterprise Value

MLYS$2.02B

PVLA$1.82B

Price

MLYS$23.37

PVLA$138.77

P/E Ratio

MLYSN/A

PVLAN/A

P/S Ratio

MLYS0.00x

PVLA46.64x

EV/Sales

MLYS0.00x

PVLA0.00x

EV/EBITDA

MLYS0.00x

PVLA0.00x

P/B Ratio

MLYS3.79x

PVLA8.80x

P/FCF Ratio

MLYSN/A

PVLAN/A

EV/FCF

MLYS-5.96x

PVLA-49.96x

PEG Ratio

MLYSN/A

PVLAN/A

Forward P/E (NTM)

MLYSN/A

PVLAN/A

Forward P/S (NTM)

MLYS30.20x

PVLAN/A

Revenue (TTM)

MLYS$0

PVLA$0

Revenue Growth (YoY)

MLYSN/A

PVLA-97.2%

Forward Rev Growth

MLYS106.7%

PVLA287.4%

Gross Margin (TTM)

MLYS0.0%

PVLA0.0%

Operating Margin (TTM)

MLYS0.0%

PVLA0.0%

EBITDA Margin (TTM)

MLYS0.0%

PVLA0.0%

Net Margin (TTM)

MLYS0.0%

PVLA0.0%

FCF Margin (TTM)

MLYSN/A

PVLAN/A

Net Income (TTM)

MLYS$-350M

PVLA$-62M

FCF (TTM)

MLYS$-339M

PVLA$-37M

EPS (TTM)

MLYS-$4.13

PVLA-$4.30

ROE (TTM)

MLYS-5797.0%

PVLA-4784.0%

ROA (TTM)

MLYS-5415.0%

PVLA-3833.0%

ROIC (TTM)

MLYS-5571.0%

PVLA-4172.0%

Cash

MLYS$138M

PVLA$188M

Debt

MLYS$98M

PVLA$22M

Net Cash/Debt

MLYS$41M

PVLA$166M

Current Ratio (TTM)

MLYS34.46x

PVLA21.18x

Quick Ratio (TTM)

MLYS34.24x

PVLA21.01x

Debt/Equity (TTM)

MLYS0.18x

PVLA0.10x

Debt/Assets (TTM)

MLYS0.0%

PVLA0.0%

Interest Coverage (TTM)

MLYSN/A

PVLAN/A

Net Debt/EBITDA (TTM)

MLYS0.00x

PVLA0.00x

Beta

MLYS0.64

PVLA-0.19

52W Performance

MLYS-37.7%

PVLA85.4%

YTD Performance

MLYS-34.6%

PVLA38.4%

% from 52W High

MLYS-51.0%

PVLA-14.0%

% from 52W Low

MLYS8.9%

PVLA110.5%

Asset Turnover (TTM)

MLYS0.00x

PVLA0.76x

FCF Yield (TTM)

MLYS-16.5%

PVLA-1.8%

Earnings Yield (TTM)

MLYS-17.0%

PVLA-3.1%

Dividend Yield (TTM)

MLYSN/A

PVLAN/A

Rule of 40

MLYS0.0

PVLA-97.2

EV/GP/RG

MLYSN/A

PVLAN/A

Ticker research

View MLYS research View PVLA research

Metric	MLYS Mineralys Therapeutics Inc	PVLA Palvella Therapeutics Inc
Market & Valuation
Market Cap	$2.06B	$1.99B
Enterprise Value	$2.02B	$1.82B
Price	$23.37	$138.77
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	46.64x
EV/Sales	0.00x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.79x	8.80x
P/FCF Ratio	N/A	N/A
EV/FCF	-5.96x	-49.96x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	30.20x	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	-97.2%
Forward Rev Growth	106.7%	287.4%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-350M	$-62M
FCF (TTM)	$-339M	$-37M
EPS (TTM)	-$4.13	-$4.30
ROE (TTM)	-5797.0%	-4784.0%
ROA (TTM)	-5415.0%	-3833.0%
ROIC (TTM)	-5571.0%	-4172.0%
Financial Health
Cash	$138M	$188M
Debt	$98M	$22M
Net Cash/Debt	$41M	$166M
Current Ratio (TTM)	34.46x	21.18x
Quick Ratio (TTM)	34.24x	21.01x
Debt/Equity (TTM)	0.18x	0.10x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.64	-0.19
52W Performance	-37.7%	85.4%
YTD Performance	-34.6%	38.4%
% from 52W High	-51.0%	-14.0%
% from 52W Low	8.9%	110.5%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.76x
FCF Yield (TTM)	-16.5%	-1.8%
Earnings Yield (TTM)	-17.0%	-3.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-97.2
EV/GP/RG	N/A	N/A
Ticker research	View MLYS research	View PVLA research